Neurotensin Agonists: Potential in the Treatment of Schizophrenia

ISSN： 1172-7047

Source： CNS Drugs, Vol.21, Iss.1, 2007-01, pp. : 13-23

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia

By Martin Laura Kem William Freedman Robert

Psychopharmacology, Vol. 174, Iss. 1, 2004-06 ,pp. : 54-64

Springer Publishing Company

Access to resources Recommend Favorite

Neurotensin agonists as an alternative to antipsychotics

By Boules Mona Fredrickson Paul Richelson Elliott

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 4, 2005-04 ,pp. : 359-369

Informa Healthcare

Access to resources Recommend Favorite

Neuropeptide Receptor Ligands for the Treatment of Schizophrenia: Focus on Neurotensin and Tachykinins

Current Pharmaceutical Design, Vol. 21, Iss. 26, 2015-01 ,pp. : 3807-3812

Bentham Science Publishers

Access to resources Recommend Favorite

Galantamine is of potential benefit in the treatment of schizophrenia

Inpharma, Vol. 1, Iss. 1354, 2002-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

7 Nicotinic Receptor Agonists as Potential Therapeutic Drugs for Schizophrenia

Current Medicinal Chemistry - Central Nervous System Agents, Vol. 5, Iss. 3, 2005-09 ,pp. : 171-184

Bentham Science Publishers

Access to resources Recommend Favorite